Despite the recently reported disadvantages of a selective inhibitor of FGFR1, 2, and 3 in 22 cholangiocarcinoma patients with FGF/FGFR genetic alterations other than FGFR2 translocation from the interim results of flight-202 study 17, the encouraging efficacy of pan-FGFR inhibitor were reported in patients harboring these alterations with durable response 9. This evidence concerns the gene FGFR1 and cholangiocarcinoma.